Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate
January 31, 2022 08:00 ET
|
Celsion Corporation
Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 ...
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
January 27, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity...
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
January 25, 2022 06:45 ET
|
BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
January 25, 2022 06:45 ET
|
BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
January 24, 2022 06:00 ET
|
SAB Biotherapeutics, Inc.
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700...
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
January 13, 2022 17:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19
January 11, 2022 07:12 ET
|
Vir Biotechnology, Inc.
– 600,000 additional doses to be supplied to the US government for distribution in Q1 2022, enabling further access to sotrovimab nationwide – – Brings total number of doses secured to date through...
BioNTech und InstaDeep entwickeln und testen erfolgreich ein Frühwarnsystem zur Erkennung potenzieller Hochrisikovarianten von SARS-CoV-2
January 11, 2022 07:00 ET
|
BioNTech SE
Das Frühwarnsystem kombiniert Strukturmodellierung von Spike-Proteinen mit künstlicher Intelligenz (KI), um Hochrisikovarianten von SARS-CoV-2 zu erkennen und zu überwachen; dabei können...
BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants
January 11, 2022 07:00 ET
|
BioNTech SE
Early Warning System combines Spike protein structural modeling with artificial intelligence (AI) to detect and monitor high-risk SARS-CoV-2 variants, identifying >90% of WHO-designated variants on...
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
January 10, 2022 20:45 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...